 Codexis, Inc. CDXS, a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D. at the companys 2020 Annual Meeting of Stockholders held earlier today. We are delighted to welcome these two highly qualified professionals to our board, both of whom bring exceptional experience in biotherapeutics development and commercialization at a time when we are increasing our focus on this business segment, said Bernard J. Kelley, Codexis Chairman. Dr. Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing. 